Clinical Infectious Diseases (CID) is published under the auspices of the Infectious Diseases Society of America. The scope of the journal includes pathogenesis, clinical investigation, medical microbiology, diagnosis, immune mechanisms, and the treatment of diseases caused by infectious agents. It is our intention to publish clinically relevant articles of current interest in these areas.

Evaluation of Manuscripts

All submitted manuscripts are initially read by the editor and the deputy editor. Approximately one-third of the manuscripts submitted to CID are declined, without further review, on the basis of general content. If a manuscript is judged to be of interest to the readers of CID, it is sent to outside experts who are asked to read and analyze the paper within 3 weeks. Upon return from reviewers, the manuscript and its reviews are evaluated by an associate editor, who participates with the editor in making a decision to reject the manuscript, accept it, or invite a revision. Authors are usually notified about the acceptability of a manuscript within 8 weeks from its initial receipt in the editorial office, although delays in the review process are occasionally unavoidable. In general, the reports of outside experts are sent to authors anonymously as constructive, objective criticism of the work.

Publication

If the article is accepted for publication, the editorial office will mail a publication agreement to the corresponding author, assigning copyright to the University of Chicago Press; this form must be signed and returned to the editorial office. Delay in doing so will cause delay in publication.

The journal reserves the right to edit for clarity, conciseness, grammar, and CID format. Authors have an opportunity to review these changes when they correct their proofs. Authors will be charged for excess alterations other than the correction of errors or misleading statements.

Policy Regarding Print versus Electronic Publication in CID

All articles accepted for publication in CID will be published in the electronic version on the Internet (http://www.journals.uchicago.edu/CID/) and indexed by MEDLINE. Many but not all of these articles will also be published in a subsequent printed edition of CID. Because of page constraints in the printed journal, some accepted articles will not appear in the printed version. If the manuscript is accepted only for the electronic version, the corresponding author will be so notified at acceptance (and will have an opportunity to withdraw the paper if desired). Articles published only in the electronic version will be listed in the printed version of CID by title and complete authors and accompanied by a short abstract. Articles published only in the electronic version of CID will still be fully indexed by MEDLINE.

Redundant or Duplicate Publication

Redundant or duplicate publication is publication of a paper that overlaps substantially with one already published. Readers of primary source periodicals deserve to be able to trust that what they are reading is original unless there is a clear statement that the article is being republished by the choice of the author and editor. The bases of this position are international copyright laws, ethical conduct, and cost-effective use of resources.

Most journals do not wish to receive papers on work that has already been reported in large part in a published article or is contained in another paper that has been submitted or accepted for publication elsewhere, in print or in electronic media. This policy does not preclude the journal’s considering a paper that has been rejected by another journal, or a complete report that follows publication of a preliminary report, such as an abstract or poster displayed for colleagues at a professional meeting. Nor does it prevent the journal from considering a paper that has been presented at a scientific meeting but not published in full or that is being considered for publication in a proceedings or similar format. Press reports at scheduled meetings will not usually be regarded as breaches of this rule, but such reports should not be amplified by additional data or copies of tables and illustrations.

When submitting a paper, the author should always make a full statement to the editor about all submissions and previous reports that might be regarded as redundant or duplicate publication of the same or very similar work. The author should alert the editor if the work includes subjects about which a previous report has been published. Any such work should be referred to and referenced in the new paper. Copies of such material should be included with the submitted paper, to help the editor decide how to handle the matter.

If redundant or duplicate publication is attempted or occurs without such notification, authors should expect editorial ac-
tion to be taken. At the least, prompt rejection of the submitted manuscript should be expected. If the editor was not aware of the violations and the article has already been published, then a notice of redundant or duplicate publication will probably be published with or without the author’s explanation or approval.

Preliminary reporting, to public media, governmental agencies, or manufacturers, of scientific information described in a paper or a letter to the editor that has been accepted but not yet published violates the policies of many journals. Such reporting may be warranted when the paper or letter describes major therapeutic advances or public health hazards such as serious adverse effects of drugs, vaccines, other biological products, or medicinal devices, or reportable diseases. This reporting should not jeopardize publication but should be discussed with and agreed upon by the editor in advance.

**Conflict of Interest**

Conflict of interest exists when a participant in the publication process—author, reviewer, or editor—has ties to activities that could inappropriately influence his or her judgment, whether or not judgment is in fact affected.

*Authors.* When they submit a manuscript, whether an article or a letter, authors are responsible for disclosing financial and other potential conflicts of interest that might bias their work. They should acknowledge, in a footnote on the title page, all financial support for the work and other financial and personal connections to the work. The corresponding author should state in the transmittal letter, on behalf of all authors, that all potential conflicts of interest have been disclosed.

*Project-specific industry support for research.* Scientists have an ethical obligation to submit creditable research results for publication. Moreover, as the persons directly responsible for their work, scientists should not enter into agreements that interfere with their control over the decision to publish the papers they write. When they submit a manuscript, whether an article or a letter, authors are responsible for recognizing and disclosing financial and other conflicts of interest that might bias their work.

*Reviewers.* External peer reviewers should disclose to editors any potential conflicts of interest that could bias their opinions of the manuscript, and they should offer to disqualify themselves from reviewing specific manuscripts if they believe a conflict may exist. The editors must be made aware of reviewers’ conflicts of interest to interpret the reviews and judge for themselves whether the reviewer should be disqualified. Reviewers should not use knowledge of the work, before its publication, to further their own interests.

*Editors and staff.* Editors and staff who make final decisions about manuscripts should have no personal or financial involvement in any of the issues they might judge.

**Content Charges**

For manuscripts accepted for publication, content charges will be assessed as follows: $50 per page for 6 or fewer printed pages, and $75 per page for each additional page beyond 6. The publisher will bill the author concurrently for content charges and reprints. Invited articles, correspondence related to articles recently published in *CID*, and articles that appear only in the electronic edition will not be subject to content charges. In unusual circumstances, the editors may waive content charges.

**Types of Articles Published in CID**

Papers may be submitted in the following categories; however, final determination of any article’s category of publication (e.g., Major Article or Brief Report) is made by the editors upon acceptance of the article. For further details on manuscript preparation, consult the Instructions for Authors.

*Major Articles.* Clinically relevant investigations within our scope of interests, as defined above. These are uninvited articles with a length of 3000 words and approximately 30 references. Figures and tables may be included as needed.

*Brief Reports.* Condensed articles with a highly focused message and minimum of methodologic detail, limited to 1500 words, 10–12 references, and one table or figure. Case reports (a single case or a collection of cases) with a concise review of the literature may also be submitted in this category. Priority will be given to cases representing common problems with unusual presentations, or novel perspectives or solutions.

*Review Articles.* Reviews of topics related to clinical aspects of infection and other subjects within our scope of interests, as defined above. Reviews should generally not exceed 3000 words. Authors are encouraged to consult the literature and past issues of *CID* to determine which subjects have not received recent attention.

*Correspondence.* Letters to the Editor must address a recent previous publication in *CID* or raise an issue of interest to the infectious diseases community. Letters should not exceed 500 words. Short papers containing original data or observations should be submitted as Brief Reports, not Letters, and will undergo peer review.

*Editorials and Editorial Commentaries.* These are generally invited articles; however, unsolicited manuscripts of an editorial nature will be considered for the Viewpoints section. Some may be presented in a point-counterpoint fashion.

*Special Sections.* Articles for the special sections will gen-
erally be minireviews solicited from experts by the Special Section Editors, but the editors will also consider unsolicited articles.

**Book Reviews.** The editors welcome books and other material related to the field of infectious diseases for review in the Book Review section. Publishers interested in having their books reviewed should send two copies to the editorial office (address below). Not all material submitted will necessarily be presented.

**Photo Quiz/Arcanum.** Photo Quiz submissions should feature one or more striking photographs relating to a case likely to be of interest to practitioners of infectious diseases. The Arcanum feature is meant to entertain and educate the CID readership by presenting as a question some arcane detail of the practice of infectious diseases. Details for the preparation and submission of either can be found at the end of the Instructions for Authors.

**Supplements.** CID will publish supplements on any clinical topic within its scope, as defined above. Supplements must be planned with the editor. Supplement manuscripts must be reviewed and revised appropriately by the guest editor(s) prior to submission to CID. Experts for the journal will additionally review them. The author of a paper in a supplement has sole responsibility for the content of a paper submitted under his or her name by a third party (guest editor, commercial editing service, or sponsor of the supplement). For additional information, please contact Sherwood L. Gorbach, M.D., Editor (sherwood.gorbach@tufts.edu), Joan B. Daniels, Managing Editor (jdaniels@press.uchicago.edu), or Everett Conner, Publications Manager (econner@press.uchicago.edu).